This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: National Institute of Health and Medical Research, Centre National De La Recherche Scientifique, Université Versailles Saint-Quentin-En-Yvelines. Active years: 2015-2016.
Company Filing History:
2 out of 1,853 
1 out of 5,383 
1 out of 9 Years Active: 2015-2016
Title: Alexandre Denoyer: Innovator in Ocular Research
Introduction
Alexandre Denoyer is a prominent inventor based in Paris, France. He has made significant contributions to the field of ocular research, particularly in understanding and treating conditions such as glaucoma. With a total of 2 patents, Denoyer's work has the potential to impact both veterinary and human medicine.
Latest Patents
Denoyer's latest patents include a method for increasing intraocular pressure in animals. This method involves the ocular administration of a solution containing benzalkonium chloride (BAK). The invention provides a valuable animal model for studying the pathophysiological mechanisms involved in ocular hypertension and glaucoma. Additionally, he has developed a pharmaceutical composition aimed at treating glaucoma, which includes a compound that acts as an antagonist of CXCR3 or inhibits the expression of the CXCR3 receptor.
Career Highlights
Throughout his career, Denoyer has worked with esteemed institutions such as the National Institute of Health and Medical Research and the Centre National de la Recherche Scientifique. His research has focused on innovative approaches to understanding and treating ocular diseases, contributing to advancements in the field.
Collaborations
Denoyer has collaborated with notable colleagues, including William Rostene and Christophe Baudouin. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic strategies.
Conclusion
In summary, Alexandre Denoyer is a dedicated inventor whose work in ocular research has led to significant advancements in understanding and treating glaucoma. His innovative patents and collaborations highlight his commitment to improving health outcomes in both animals and humans.